Acoramidis ATTR Cm denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for acoramidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issued a Not-FDA-Approved Denial for Acoramidis in ATTR-CM — and How to Appeal

A "not-FDA-approved" denial means Aetna's system or reviewer has flagged that the requested use of acoramidis either (a) lacks FDA approval entirely, or (b) is being requested for an indication, population, or use that is outside the scope of the FDA-approved label. This type of denial is one of the most directly correctable — if the use is in fact FDA-approved, the error can be demonstrated with the prescribing label itself.

Before proceeding, verify the current FDA-approval status of acoramidis and its approved indication(s) by consulting the current FDA-approved prescribing information (available via DailyMed or the FDA's drug database). Do not rely on this page for that determination — regulatory status can change, and only the official label is authoritative.

## Why This Denial Is Appealable

Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review of any denial, including one based on regulatory status. If the FDA has approved acoramidis for the indication being treated, that is direct evidence that the denial premise is incorrect. If the use is off-label, a different argument applies — off-label uses supported by recognized compendia or professional society guidelines may also be coverable under many plan terms. External review is available within approximately four months of a final internal denial.

## Your Appeal Timeline

• Internal appeal: File within 180 days of the denial notice (confirm on your Explanation of Benefits).
• External review: Within approximately four months of the final internal denial.
• Expedited review: Request this track if the patient's condition is urgent.

## Documentation to Gather

1. Current FDA prescribing label for acoramidis: Obtain the official label (from DailyMed or the FDA website) and attach it to your appeal. It documents the approved indication(s), the approved patient population, and the regulatory basis for use. 2. Confirmation that the requested use matches the approved indication: A statement from the prescribing cardiologist that the patient's diagnosis and the requested use fall within the FDA-approved indication. 3. Confirmed ATTR-CM diagnosis documentation: Chart records establishing the diagnosis that aligns with the approved indication. 4. Prescriber medical-necessity letter: A letter from the treating cardiologist confirming the FDA-approved use, the diagnosis, and the clinical rationale. 5. Applicable guideline reference: If relevant, note that the relevant cardiology society guideline organization supports use of TTR-targeting therapy for this patient's disease stage.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal Evidence | |---|---| | Drug not FDA-approved | [Attach current FDA label showing approval] | | Use outside approved indication | [Prescriber letter confirming indication match] | | Patient population outside label | [Chart diagnosis matching label population] | | Medical necessity for this patient | [Cardiologist clinical rationale] |

If this denial was issued in error — because the drug is in fact approved for the diagnosed condition — state that plainly and concisely at the top of the appeal letter, attach the FDA label, and request immediate reconsideration.